NLRP3 and cryopyrin-associated periodic syndrome: A recent study showed that the molecular target of diarylsulfonylurea inhibitors is an NACHT domain of NLRP3, and as a consequence, MCC950 fails to efficiently inhibit the cryopyrin-associated periodic syndrome (CAPS) forms of NLRP3 [89].